Africa Western and Central vs Liberia: Access to anti-retroviral drugs, female
Africa Western and Central
83.1%
in 2024
Liberia
96.0%
in 2024
Africa Western and Central rank
14th
Liberia rank
14th
Access to anti-retroviral drugs, female over time
- Africa Western and Central
- Liberia
How they compare
Liberia currently reports 96.0% against 83.1% in Africa Western and Central, a difference of 12.9%.
That makes Liberia's figure about 1.2 times Africa Western and Central's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Liberia ahead.
Africa Western and Central ranks 14th and Liberia ranks 14th of 19 groups.
Across the 3 decades both report, Africa Western and Central averaged higher in 2 and Liberia in 1.
Head to head by decade
| Decade | Africa Western and Central | Liberia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.6% | 1.7% | 2.9% | Africa Western and Central |
| 2010s | 40.2% | 27.4% | 12.8% | Africa Western and Central |
| 2020s | 74.6% | 77.2% | 2.6% | Liberia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Africa Western and Central or Liberia?
- Liberia, at 96.0% against 83.1% in Africa Western and Central as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Africa Western and Central and Liberia?
- 12.9%, with Liberia ahead.
- How many years of comparable data are there for Africa Western and Central and Liberia?
- 25 years are reported by both, from 2000 to 2024.
- How do Africa Western and Central and Liberia rank globally for access to anti-retroviral drugs, female?
- Africa Western and Central ranks 14th and Liberia ranks 14th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.